Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 34, Issue 2, 2002, Pages 199-206

  Süoglu, Özlem D ^a,b   Elkabes, Berna ^a   Sökücü, Semra ^a   Saner, Günay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Children; Hepatitis C; Interferon alpha; Iron overload; Ribavirin

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; MALE; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 0036207001     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200202000-00018     Document Type: Article

References (66)

1. Hepatitis C
2. Therapy of hepatitis C: Meta-analysis of interferon 2b trials
3. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
4. Response to interferon therapy in children with chronic hepatitis C
5. Low virological response to interferon in children with chronic hepatitis C
6. Treatment of naive patients with chronic hepatitis C
7. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
9. Interferon alpha 2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
10. Interferon alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
11. The distribution of hepatitis C virus genotypes in Turkish patients
12. Hepatitis C virus genotypes in chronic hemodialysis patients
13. Virology of Hepatitis C Virus
14. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B
15. Classification of chronic hepatitis: Diagnosis, grading and staging
16. Definition of response to antiviral therapy in chronic hepatitis C
17. Hepatitis C: Global prevalence
18. Natural history of hepatitis C: Its impact on clinical management
19. Spontaneous remission of chronic hepatitis C in children
20. Recombinant interferon alpha therapy in children with chronic hepatitis C
21. Lymphoblastoid interferon alfa treatment in chronic hepatitis C
22. Long term efficacy of interferon alfa therapy for chronic hepatitis C in children
23. Effect of iron overload on the response to recombinant interferon alfa treatment in transfusion dependent patients with thalassemia major and chronic hepatitis C
24. Chronic hepatitis C infection in childhood and early cirrhosis: It is possible?
25. Hepatitis C virus infection in pediatric patients
26. Chronic hepatitis C in children: The pathologic and clinical spectrum
27. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adult patients
28. Histopathology of the liver in children with chronic hepatitis C viral infection
29. The progression of hepatic inflammation and fibrosis in children with hepatitis C
30. Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study
31. Interferon for chronic hepatitis C in patients cured of malignancy
32. Efficacy of interferon in treating chronic hepatitis C in children with a history of acute leukemia
33. Interferon alpha2b treatment of chronic hepatitis C in children with hemophilia
34. Efficacy of interferons in treating children with chronic hepatitis C
35. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease
36. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C
37. Long-term efficacy of α-interferon in β-thalassemics with chronic hepatitis C
38. Interferon alpha treatment of chronic hepatitis C virus infection in children
39. Interferon alpha treatment for chronic hepatitis C in children
40. Interferon alfa treatment of chronic hepatitis C in children with hemophilia
41. Analysis of interferon monotherapy trials in children with HCV
42. Efficacy of interferon alpha treatment in Japanese children with chronic hepatitis C
43. Treatment of chronic hepatitis C with recombinant interferon α2b in childhood
44. Interferon and hepatitis C - Factors predicting therapeutic outcome
45. Iron overload and response to α-interferon in chronic hepatitis C
46. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
47. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: A predictive marker for IFN therapy
48. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
49. Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus
50. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype
51. Racial differences in responses to therapy with interferon in chronic hepatitis C
52. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement
53. Ribavirin treatment in combination with interferon alfa in dialysis patients with chronic hepatitis C infection
54. Treatment of hepatitis C in special groups
55. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients
56. Interferon-α and ribavirin treatment of hepatitis C in children with malignancy in remission
57. Treatment of chronic hepatitis C with interferon and ribavirin in children surviving pediatric malignancy
58. Safety, efficacy and pharmacokinetics of interferon alfa-2b and ribavirin in children with hepatitis C
59. Hemosiderin deposition in portal endothelial cells is a histologic marker predicting poor response to interferon-α therapy in chronic hepatitis C
60. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin
61. The biology of interferon-α and the clinical significance of anti-interferon antibodies
62. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection
63. Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs
64. Neutralizing antibodies to interferon-α: Relative frequency in patients treated with different interferon preparations
65. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C